Rapport Therapeutics (RAPP) CDO Yeleswaram Krishnaswamy Sells 404 Shares

What Happened

Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 404 shares in an open‑market transaction on August 19, 2026. The shares were disposed at $49.90 each for a total transaction value of $20,160. This was a sale (not a purchase); such sales are often routine cash‑management or pre‑scheduled transactions rather than a direct bullish signal.

Key Details

• Transaction date: 2026-08-19 (reported on Form 4 filed 2026-08-20)
• Transaction type/code: Sale (S) — open market/private sale reported as a sale
• Price and amount: 404 shares at $49.90 per share; total $20,160
• Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for post-transaction holdings
• Footnote: Transaction executed pursuant to a Rule 10b5‑1 trading plan adopted December 10, 2025 (pre‑scheduled plan)
• Timeliness: Filed the next day (Aug 20, 2026); not indicated as late in the provided data

Context

A 10b5‑1 trading plan means the sale was made under a pre-established schedule, which is intended to insulate the reporting person from trading on material nonpublic information. For retail investors, purchases by insiders tend to carry more informational weight than routine sales; a single modest sale like this typically reflects personal liquidity or plan-driven activity rather than a change in company outlook. For full ownership details and any additional related transactions, consult the complete Form 4 (Accession: 0001193125-26-359189).